BHRT vs traditional HRT: which should I ask for and where?

Short answer

• Start by discussing FDA‑approved HRT with a clinician who knows menopause medicine (board‑certified gynecologist, reproductive endocrinologist, or a menopause specialist). For most people, an FDA‑approved regimen (standard HRT) is safer and better studied.
• Consider compounded bioidentical HRT (BHRT) only after a careful risk/benefit discussion with an experienced clinician and if you use a PCAB‑accredited compounding pharmacy and structured monitoring.

Key differences (brief)

• Traditional (FDA‑approved) HRT: uses standard, manufactured products with known doses, quality controls, and large clinical trial safety/efficacy data.
  • Examples: Vivelle‑Dot, Climara, Alora (estradiol patches); Estrace (oral estradiol); Prometrium (micronized progesterone); Vagifem/Estring (vaginal estradiol).
  • Advantages: predictable dosing, consistent quality, insurance coverage often available, established safety/monitoring guidance.
• BHRT / compounded hormones: custom formulations prepared by compounding pharmacies (often marketed as “natural” or “exactly like your hormones”).
  • Advantages claimed: individualized dose/forms, compounded combinations.
  • Downsides: many formulations are not FDA‑tested or approved, variable potency/quality between pharmacies, limited high‑quality outcome data, potential safety unknowns.

When to ask for which

• Ask for traditional FDA‑approved HRT first if you have moderate-to-severe menopausal symptoms (hot flashes, night sweats, significant vaginal atrophy), because evidence and safety guidance are much stronger.
• Consider BHRT only if:
  • You have tried FDA‑approved options and they didn’t work or caused side effects you can’t tolerate, AND
  • Your clinician supports compounded dosing for a specific reason (allergy to an excipient, need for unusual dose/forms), AND
  • You commit to close follow‑up and lab monitoring.

What to ask your clinician (specific)

• Request a baseline evaluation: medical history (clotting, breast cancer, cardiovascular risk), breast/chest screening as appropriate, and labs as indicated (TSH, lipids, fasting glucose, and targeted hormone tests if clinically indicated).
• Ask about product options and why they recommend a specific one (e.g., transdermal estradiol patch like Vivelle‑Dot or Climara vs oral estradiol).
• If considering progesterone, ask about Prometrium (micronized progesterone) vs synthetic progestins and their different risks.
• If you’re considering compounded BHRT: ask which compounding pharmacy they use and whether it’s PCAB (Pharmacy Compounding Accreditation Board) accredited; ask for certificate of analysis and lot testing.

Where (who/where to go)

• See a clinician experienced in menopause care:
  • Board‑certified gynecologist with menopause training or a reproductive endocrinologist
  • Menopause/vasomotor symptom clinics at major centers (examples): Mayo Clinic Menopause Clinic, Cleveland Clinic Menopause Center, UCSF Menopause Program, Johns Hopkins Menopause Clinic — these centers use evidence‑based protocols and can provide second opinions.
• If you prefer telemedicine, use established telehealth programs connected with health systems or clinics that will do appropriate baseline testing and arrange follow‑up (ask about their menopause expertise).
• If you choose BHRT, use a PCAB‑accredited compounding pharmacy. One widely used example is Wedgewood Pharmacy (among others); your clinician should recommend a local, accredited compounding pharmacy and provide documentation of quality testing.

Safety and monitoring (important)

• All hormone therapies have potential risks (e.g., thromboembolism, stroke, breast cancer risk changes depending on regimen/type and duration). These risks differ by hormone type, route (oral vs transdermal), age at initiation, and individual risk factors.
• Transdermal estradiol patches are often preferred when clotting risk is a concern because they may carry a lower VTE risk than oral estrogens.
• Commit to follow‑up visits and appropriate monitoring (symptom review, periodic breast/cardiovascular risk reassessment) and stop or adjust therapy if concerning symptoms arise.

Bottom line recommendation

• Ask for an evidence‑based, FDA‑approved HRT option first (examples: transdermal estradiol patch like Vivelle‑Dot or Climara; oral estradiol like Estrace; progesterone like Prometrium) and discuss risks/benefits with a menopause‑trained clinician.
• Only pursue compounded BHRT if there is a clear, individualized reason and you use a PCAB‑accredited pharmacy with careful oversight.

If you’d like, tell me:

• your main symptoms, age, and any important medical history (clotting, breast cancer, cardiovascular disease) and I can suggest which specific HRT options might commonly be considered and questions to bring to your clinician.